# HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.

> **NCT04898504** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Oslo University Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Colorectal Cancer
- Liver Metastases
- Chemotherapy Effect

## Interventions

- **DRUG:** Floxuridine
- **PROCEDURE:** Liver Transplantation

## Key facts

- **NCT ID:** NCT04898504
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-23
- **Primary completion:** 2025-05
- **Final completion:** 2026-05
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04898504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04898504, "HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04898504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*